SRPK1 and posterior cortical atrophy: Finally, in a therapeutic proof-of-principle experiment we have shown that intraperitoneal administration of a specific SRPK1 inhibitor (SPHINX) is able to reduce tumour growth in an orthotopic mouse model of PCa.